Since 1973, Hanmi has grown to become the most spotlighted pharmaceutical company in Korea. Hanmi is vertically integrated with full capacity in manufacturing intermediates, APIs, and Finished products. Hanmi has 2 API plants (General & Cepha-dedicated) and 3 finished product plants (general, Cepha-dedicated, Bio-dedicated) in Korea, and 1 finished product plant in China. Our facilities are inspected and approved by US FDA, UK MHRA, German BGV, Japanese PMDA and Australian TGA.